According to GILD’s PR, 15% of the patients randomized to the non-placebo arm had cirrhosis. The SVR12 rate among these cirrhotic patients was 61%; however, GILD did not disclose the breakdown of cirrhotic patients by genotype as they did for the overall trial.
Market Data 
Markets 
AI
